Revenue

Revenue recognized from grants and other sources is as follows:



	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
	(In thousands)				(In thousands)
Small Business Innovative Research Grants	$	214	$	196	$	359	$	461
Vulcan Inc.	—		—		—		970
Total revenue	$	214	$	196	$	359	$	1,431

We have periodically received Small Business Innovative Research (SBIR) grants from the National Institutes of Health (NIH), which are used to support the research and development of our product candidates. We recorded revenue related to these grants of $214,000 and $196,000 for the three months ended September 30, 2014 and 2013, respectively, and $359,000 and $461,000 for the nine months ended September 30, 2014 and 2013, respectively. We recorded cost reductions to property and equipment due to assets being purchased with grant funding of $40,000 and $0 for the three and nine months ended September 30, 2014 and 2013, respectively. As of September 30, 2014, $785,000 of potential revenue remained available under these grants, if qualifying research is performed.

In October 2010, we entered into a platform development funding agreement with Vulcan Inc. and its affiliate (collectively, Vulcan) pursuant to which we received $20.0 million for our G protein-coupled receptor (GPCR) program. Of the funds received, $8.2 million was recorded as deferred revenue. The remaining deferred revenue of $970,000 was recognized as revenue during the first quarter of 2013.